Focusing on non-pharmacological and pharmacological therapies that act on inhibiting most insulin-resistance generated risk factors (such as GLP-1 RA or SGLT-2 inhibitors) is an important step in minimalizing the impact of insulin resistance in T2DM patients in order to protect them against progression towards CKD [22,23]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.